MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Alnylam Pharmaceuticals Inc

Closed

SectorHealthcare

267.08 4.76

Overview

Share price change

24h

Current

Min

252.55

Max

267.08

Key metrics

By Trading Economics

Income

28M

-84M

Sales

92M

593M

EPS

0.06

Profit margin

-14.121

Employees

2,230

EBITDA

-92M

-155M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+26.42% upside

Dividends

By Dow Jones

Next Earnings

1 May 2025

Market Stats

By TradingEconomics

Market Cap

-46M

35B

Previous open

262.32

Previous close

267.08

News Sentiment

By Acuity

50%

50%

180 / 386 Healthcare

Technical Score

By Trading Central

Confidence

Bearish Evidence

Alnylam Pharmaceuticals Inc Chart

Past performance is not a reliable indicator of future results.

Related News

12 Sept 2024, 17:01 UTC

Top News

The Brawl Taking Shape Over Pfizer's Multibillion-Dollar Heart Monopoly -- Heard on the Street -- Update

12 Sept 2024, 11:00 UTC

Top News

The Brawl Taking Shape Over Pfizer's Multibillion-Dollar Heart Monopoly -- Heard on the Street -- WSJ

Peer Comparison

Price change

Alnylam Pharmaceuticals Inc Forecast

Price Target

By TipRanks

26.42% upside

12 Months Forecast

Average 323.33 USD  26.42%

High 500 USD

Low 206 USD

Based on 22 Wall Street analysts offering 12 month price targets forAlnylam Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

22 ratings

18

Buy

4

Hold

0

Sell

Technical Score

By Trading Central

243.87 / 271.02Support & Resistance

Short Term

Bearish Evidence

Intermediate Term

Bullish Evidence

Long Term

Weak Bearish Evidence

Sentiment

By Acuity

180 / 386 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Alnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.